Anton Pozniak - Concepedia

Author

Anton Pozniak

Also Known As

A L Pozniak, A Pozniak, A. L. POZNIAK, A. L. Pozniak, A. POZNIAK, A. Pozniak, A.L. Pozniak, Anna Tostevin, Anton L Pozniak, Anton L. Pozniak

474

Publications

19.9K

Citations

H-Index

168

Concepts

All Affiliations

Chelsea and Westminster Hospital Chelsea and Westminster Hospital NHS Foundation Trust University College London University of Liverpool Imperial College London

About

Anton Pozniak is an author at Chelsea and Westminster Hospital specializing in medicine, hiv, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	31	64	5.1K
2	Health Sciences	5	5	115
3	Nursing	2	2	73
4	Education	1	1	17
5	Natural Sciences	1	1	23

Anton Pozniak

206

Publications

14.9K

Citations

H-Index

Page 1

	Year	Citations
Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV Joel E. Gallant, Edwin DeJesus, José Ramón Arribas, New England Journal of Medicine	2006	879
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials Paul E. Sax, David A. Wohl, Michael T. Yin, The Lancet Treatment And PreventionMedicineAntiviral Drug DevelopmentClinical TrialsAntiviral Therapy	2015	593
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study Pedro Cahn, Anton Pozniak, Horacio Mingrone, The Lancet Treatment And PreventionWeek 48Antiviral Drug DevelopmentAntiviral TherapyDolutegravir Versus Raltegravir	2013	507
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1 Gerd Fätkenheuer, Anton Pozniak, Margaret Johnson, Nature Medicine Treatment And PreventionMedicineImmunologyAntiviral Drug DevelopmentAntiviral Therapy	2005	490
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial Paul E. Sax, Anton Pozniak, Marisa Montes, The Lancet Hiv/aids CounsellingAntiviral Drug DevelopmentAntiviral TherapyAntiviral ResponseVirology	2017	385
Loss of blood CD11c+ myeloid and CD11c−plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load Heather Donaghy, Anton Pozniak, Brian Gazzard, Blood	2001	384
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study Linda Wittkop, Huldrych F. Günthard, Frank de Wolf, The Lancet Infectious Diseases Transmitted Drug ResistanceTreatment And PreventionHuman RetrovirusAntiviral TherapyEuropean Multicohort Study	2011	381
Episodic Sexual Transmission of HIV Revealed by Molecular Phylodynamics Fraser Lewis, G. Hughes, Andrew Rambaut, PLoS Medicine	2008	374
Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy Gillian Dean, Simon Edwards, Natalie Ives, AIDS	2002	358
Can the UNAIDS 90-90-90 target be achieved? A systematic analysis of national HIV treatment cascades Jacob Levi, Alice Raymond, Anton Pozniak, BMJ Global Health	2016	337

Page 1